Aclaris Therapeutics Stock Forecast, Price & News

Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions

Is Aclaris Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aclaris Therapeutics stock.
View analyst ratings for Aclaris Therapeutics or view top-rated stocks.

How has Aclaris Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Aclaris Therapeutics' stock was trading at $1.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ACRS shares have increased by 1,190.6% and is now trading at $13.68.
View which stocks have been most impacted by COVID-19.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a decrease in short interest in the month of October. As of October 29th, there was short interest totaling 2,230,000 shares, a decrease of 19.2% from the October 14th total of 2,760,000 shares. Based on an average trading volume of 422,400 shares, the days-to-cover ratio is presently 5.3 days. Currently, 4.9% of the company's stock are sold short.
View Aclaris Therapeutics' Short Interest.

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Aclaris Therapeutics.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.07. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 54.41% and a negative net margin of 1,187.63%.
View Aclaris Therapeutics' earnings history.

What price target have analysts set for ACRS?

4 equities research analysts have issued 12-month price targets for Aclaris Therapeutics' stock. Their forecasts range from $26.00 to $49.00. On average, they anticipate Aclaris Therapeutics' stock price to reach $35.67 in the next twelve months. This suggests a possible upside of 160.7% from the stock's current price.
View analysts' price targets for Aclaris Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the following people:

• Neal S. Walker, President, Chief Executive Officer & Director (LinkedIn Profile)
• Frank Ruffo, Chief Financial Officer & Treasurer (LinkedIn Profile)
• David Gordon, Chief Medical Officer (LinkedIn Profile)
• Joseph B. Monahan, Chief Scientific Officer
• Kamil Ali-Jackson, Secretary, Chief Legal & Chief Compliance Officer (LinkedIn Profile)

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics CEO Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among Aclaris Therapeutics' employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Aclaris Therapeutics' key competitors?

Some companies that are related to Aclaris Therapeutics include Arena Pharmaceuticals (ARNA), Mawson Infrastructure Group (WIZP), Hypera (HYPMY), Cryoport (CYRX), Intra-Cellular Therapies (ITCI), Amicus Therapeutics (FOLD), Cytokinetics (CYTK), Arcus Biosciences (RCUS), Dicerna Pharmaceuticals (DRNA), Schrödinger (SDGR), Prestige Consumer Healthcare (PBH), OPKO Health (OPK), PTC Therapeutics (PTCT), Aurinia Pharmaceuticals (AUPH) and Pacira BioSciences (PCRX).
View all of ACRS's competitors.

What other stocks do shareholders of Aclaris Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX).

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (8.85%), Rock Springs Capital Management LP (6.21%), BlackRock Inc. (6.19%), Commodore Capital LP (3.58%), Renaissance Technologies LLC (3.30%) and BVF Inc. IL (2.24%). Company insiders that own Aclaris Therapeutics stock include David N Gordon, Frank Ruffo, Kamil Ali-Jackson and Neal Walker.
View institutional ownership trends for Aclaris Therapeutics.

Which institutional investors are selling Aclaris Therapeutics stock?

ACRS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Two Sigma Investments LP, Parkman Healthcare Partners LLC, Atom Investors LP, Assenagon Asset Management S.A., Point72 Asset Management L.P., Asymmetry Capital Management L.P., and Perceptive Advisors LLC. Company insiders that have sold Aclaris Therapeutics company stock in the last year include David N Gordon, Frank Ruffo, Kamil Ali-Jackson, and Neal Walker.
View insider buying and selling activity for Aclaris Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Aclaris Therapeutics stock?

ACRS stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Commodore Capital LP, Great Point Partners LLC, Invesco Ltd., BVF Inc. IL, Schonfeld Strategic Advisors LLC, and Jetstream Capital LLC.
View insider buying and selling activity for Aclaris Therapeutics or or view top insider-buying stocks.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $13.68.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics has a market capitalization of $837.59 million and generates $6.48 million in revenue each year. The biotechnology company earns $-51.01 million in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does Aclaris Therapeutics have?

Aclaris Therapeutics employs 59 workers across the globe.

What is Aclaris Therapeutics' official website?

The official website for Aclaris Therapeutics is www.aclaristx.com.

Where are Aclaris Therapeutics' headquarters?

Aclaris Therapeutics is headquartered at 640 LEE ROAD SUITE 200, WAYNE PA, 19087.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at (484) 324-7933, via email at [email protected], or via fax at 484-320-2344.